Aligos Presents Clinical Advances in Hepatitis B and Coronavirus Inhibitor Programs
Aligos presented clinical progress for hepatitis B and coronavirus treatments at CROI. Pevifoscorvir showed strong viral suppression, while ALG-097558 provided dosing data for impaired patients.
ALGSclinical trialhepatitis B virus (HBV)